- China’s 2022-revised 《反垄断法》 empowers SAMR to review concentrations that fall below the notification thresholds where they may eliminate or restrict competition.
中国2022年修订的《反垄断法》授权市场监管总局对未达申报标准、但可能排除限制竞争的集中进行审查。- “Killer” or “sniping” (掐尖式) acquisitions—buying a nascent rival to discontinue or absorb it—are a stated SAMR enforcement priority, especially in the platform economy.
“扼杀式”或”掐尖式”收购——收购新生竞争对手以停用或吸收之——是市场监管总局明确的执法重点，尤其在平台经济领域。- Below-threshold deals are not a safe harbour; the authority can call them in, impose remedies, or unwind completed transactions.
未达门槛的交易并非安全港；监管可主动立案，附加救济，或撤销已完成的交易。- The theory targets potential competition: a small or pre-revenue target’s future trajectory is what makes the deal reviewable.
该理论针对潜在竞争：标的虽小或尚无营收，其未来轨迹正使交易具有可审查性。- As of 2026, the focus has extended from platforms to biotech, semiconductors, and AI, where a startup’s talent or IP is the real asset.
截至2026年，重点已从平台延伸至生物医药、半导体及人工智能，其中初创企业的人才或知识产权才是真正资产。- Entrants should document a genuine, pro-competitive rationale and preserve standalone-viability evidence for any acquisition of an early-stage rival.
准入者应就收购早期竞争对手记录真实、促进竞争的理据，并保存其独立存续可行性的证据。
Killer-Acquisition Scrutiny in China: Below-Threshold Review | 中国”掐尖式”并购审查：未达门槛的审查
The Legal Hook: Below-Threshold Review
A defining innovation of the 2022 《反垄断法》 amendment is explicit authority for the enforcer to examine concentrations that do not meet the turnover notification thresholds yet “have or may have the effect of eliminating or restricting competition.” This closes the gap that previously let small, strategic acquisitions escape scrutiny simply because the target’s revenue was negligible. SAMR may, on its own initiative or following a complaint, open a below-threshold review—even after closing.
What Is a “Killer” or “Sniping” Acquisition?
The term “killer acquisition” (and its Chinese framing 掐尖式并购 / 猎杀式并购) describes a dominant firm buying an emerging competitor chiefly to shut it down, shelf the product, or absorb its talent and IP rather than to compete with it. The competitive harm is forward-looking: the market loses a future rival, and innovation is chilled. In platform and deep-tech contexts, the acquired asset is often pre-revenue, so classic turnover-based thresholds would never catch it—hence the below-threshold power is the relevant tool.
Why 2026 Makes This Salient
Entering 2026, several forces elevate below-threshold scrutiny:
- Platform precedent. SAMR’s platform-economy guidance names eliminating potential competition as a core concern, and 掐尖式并购 is repeatedly cited in enforcement rhetoric.
- Deep-tech race. In semiconductors, AI, and biotech, acquisitions of tiny startups for their talent or patents are strategically loaded; the real value is not current sales but future capability.
- Talent and data. Buying a team or dataset to neutralize a rival’s trajectory is exactly the harm the below-threshold rule targets.
How SAMR Assesses These Deals
The authority looks beyond current overlap to potential competition:
- Would the target, absent the deal, likely have become a significant rival?
- Is the acquirer a dominant or strategically placed firm?
- Does the transaction remove a nascent competitive constraint?
- Is there a genuine efficiency or pro-competitive rationale, or merely elimination?
Evidence of “shelving” intent—internal plans to discontinue the product, retain talent only, or refuse to invest—sharpens the case against the deal.
Remedies and Consequences
For below-threshold deals found anticompetitive, SAMR may:
- Prohibit the transaction;
- Order divestiture or restructuring of the acquired asset;
- Impose behavioural remedies (e.g., keep the product alive, license the technology, maintain investment);
- Unwind a completed concentration and impose turnover-based fines.
Because the acquirer may already have integrated the target, unwinding is disruptive and value-destroying—so the ex ante risk calculus matters more than the (often low) notification threshold.
2026 Practice Notes
- The below-threshold power is used selectively, not as a dragnet; cases cluster in platform, tech, and innovation-heavy sectors.
- SAMR signals intent through guidelines and public statements more than through a fixed numerical trigger, so sector context governs.
- Acquirers of early-stage rivals should expect that a deal’s *strategic logic*, not its size, determines scrutiny.
Practical Guidance for Entrants
- Do not assume “small = safe.” A below-threshold acquisition of a rival still invites review if its trajectory matters.
- Document pro-competitive rationale. Business plans, investment commitments, and roadmaps showing the target will thrive post-deal are protective.
- Preserve standalone-viability evidence. Demonstrate the target was not on a clear path to become a rival, or that the deal genuinely accelerates its offering.
- Consider voluntary engagement. Where a deal is sensitive, a proactive explanation to SAMR can pre-empt a contested proceeding.
- Contract for remediation. Allocate unwinding and remedy risk in the SPA, with appropriate long-stop dates.
Bottom Line
The below-threshold review power reframes China’s merger control: size is no longer the sole gate. For 2026, any acquisition by a dominant or strategically placed firm of an early-stage innovator—especially in platforms, AI, semiconductors, or biotech—should be planned as if scrutinised for its effect on future competition, with the evidentiary file built accordingly.
中国”掐尖式”并购审查：未达门槛的审查
法律抓手：未达门槛的审查
2022年《反垄断法》修订的一项标志性创新，是明确授权执法机关审查未达营业额申报标准、但”具有或者可能具有排除、限制竞争效果”的经营者集中。这填补了此前的漏洞——即小型战略性收购仅因标的营收微薄便可逃避审查。市场监管总局可主动或依举报，开展未达门槛审查，甚至在交割后启动。
何为”扼杀式”或”掐尖式”收购？
“扼杀式收购”（中文亦称掐尖式并购 / 猎杀式并购）指支配企业收购新兴竞争对手，主要目的为关停、搁置产品，或吸收其人才与知识产权，而非与之竞争。其竞争损害是前瞻性的：市场失去一个未来竞争对手，创新受抑。在平台与深科技场景中，被收购资产常处于尚无营收阶段，经典营业额门槛本无从捕获——因此未达门槛的审查权才是适用工具。
2026年为何凸显
进入2026年，多重力量抬升了未达门槛审查：
- 平台先例。 市场监管总局平台经济指引将消除潜在竞争列为核心关切，”掐尖式并购”在执法论述中屡被援引。
- 深科技竞赛。 在半导体、人工智能与生物医药领域，为人才或专利而收购微型初创企业具有战略载荷；真正价值不在当前销售，而在未来能力。
- 人才与数据。 收购团队或数据集以中性化对手轨迹，正是未达门槛规则所欲针对的损害。
市场监管总局如何评估此类交易
监管超越当前重叠，审视潜在竞争：
- 若交易不发生，标的是否可能成为重要竞争对手？
- 收购方是否为支配或具战略地位的企业？
- 交易是否消除了新生的竞争约束？
- 是否存在真实的效率或促进竞争理据，抑或仅为消除？
“搁置”意图的证据——内部关停产品、仅留人才、拒绝投入的计划——会使案件对交易更为不利。
救济与后果
对认定具反竞争效果的未达门槛交易，市场监管总局可：
- 禁止交易；
- 责令剥离或重组被收购资产；
- 附加行为性救济（如保持产品存续、许可技术、维持投入）；
- 撤销已完成的集中，并处罚以营业额为基础的罚款。
由于收购方可能已整合标的，撤销具有破坏性且摧毁价值——因此事前的风险权衡，比（往往很低的）申报门槛更关键。
2026年实践要点
- 未达门槛审查权被选择性使用，而非撒网；案件集中于平台、科技及创新密集型行业。
- 市场监管总局更多通过指引与公开表态释放意图，而非固定数值触发，故行业语境决定一切。
- 收购早期竞争对手者须预期：决定审查的是交易的*战略逻辑*，而非其规模。
准入者实务指引
- 勿假定”小即安全”。 未达门槛但轨迹重要的竞品收购，仍会招致审查。
- 记录促进竞争的理据。 商业计划、投入承诺及标的交易后仍将壮大的路线图，具有保护作用。
- 保存独立存续可行性证据。 证明标的并非清晰走向成为竞争对手，或交易确实加速了其产品供给。
- 考虑主动沟通。 交易敏感时，主动向市场监管总局说明可避免陷入争议的程序。
- 在合同中约定补救。 于协议中分配撤销与救济风险，并设置适当的最晚截止日。
要点总结
未达门槛审查权重塑了中国经营者集中制度：规模不再是唯一关口。就2026年而言，任何支配或具战略地位企业对早期创新者的收购——尤其在平台、人工智能、半导体或生物医药领域——都应按”审查其对未来竞争的影响”来规划，并据此构建证据案卷。
Sources
- 全国人民代表大会常务委员会 — 《反垄断法》（2022年修订，2022年8月1日施行，含未达标准集中的审查授权）
- 国家市场监督管理总局 (SAMR) — 《关于平台经济领域的反垄断指南》（2021年，明确消除潜在竞争关切）
- 国家市场监督管理总局 (SAMR) — 经营者集中审查相关规定及未达门槛集中审查实施口径
- 国务院 (State Council) — 平台经济与重点领域反垄断相关部署